A combination of serial F-18 FDG-PET and cognitive analyses has shed light on the progression of Alzheimer's disease. A study published in the Journal of Nuclear Medicine measured the spatial distribution of FDG over time in the brains of 51 participants divided into two groups: healthy controls and patients with mild cognitive impairment. Results showed a correlation between significant rFTC decline and longitudinal cognitive deterioration. "Such patient-based comparison is potentially less sensitive to metabolic heterogeneities across subjects and might reveal interesting links between biologic and cognitive markers of the AD state," the authors wrote of their approach.
Published in Brief: